ALX Oncology Holdings Inc. (ALXO)

Alx Oncology Holdings Inc (ALXO) is a clinical-stage immuno-oncology company that develops therapies to treat cancer. The company is focused on developing therapies that target CD47, a molecule that acts as a "don't eat me" signal to prevent the immune system from attacking cancer cells. ALXO's lead candidate, ALX148, is an investigational CD47-blocking therapeutic that has shown promising results in preclinical and clinical studies.

ALXO is also developing ALX0361, a fusion protein that combines a potent PD-1 checkpoint inhibitor with a CD80 co-stimulatory agonist. This approach is designed to both block the PD-1 pathway, which can suppress the immune response to cancer, and activate the CD28 pathway, which can enhance the immune response to cancer.

ALXO is also exploring the potential of CD47-targeting therapies in combination with other immuno-oncology agents, such as PD-1/PD-L1 inhibitors and chemotherapy.

ALXO went public in July 2020 and is listed on the Nasdaq Global Select Market under the ticker symbol "ALXO." The company is headquartered in Burlingame, California.